Abstract

BackgroundMuch has been invested in big data and artificial intelligence-based solutions for healthcare. However, few applications have been implemented in clinical practice. Early economic evaluations can help to improve decision-making by developers of analytics underlying these solutions aiming to increase the likelihood of successful implementation, but recommendations about their use are lacking. The aim of this study was to develop and apply a framework that positions best practice methods for economic evaluations alongside development of analytics, thereby enabling developers to identify barriers to success and to select analytics worth further investments.MethodsThe framework was developed using literature, recommendations for economic evaluations and by applying the framework to use cases (chronic lymphocytic leukaemia (CLL), intensive care, diabetes). First, the feasibility of developing clinically relevant analytics was assessed and critical barriers to successful development and implementation identified. Economic evaluations were then used to determine critical thresholds and guide investment decisions.ResultsWhen using the framework to assist decision-making of developers of analytics, continuing development was not always feasible or worthwhile. Developing analytics for progressive CLL and diabetes was clinically relevant but not feasible with the data available. Alternatively, developing analytics for newly diagnosed CLL patients was feasible but continuing development was not considered worthwhile because the high drug costs made it economically unattractive for potential users. Alternatively, in the intensive care unit, analytics reduced mortality and per-patient costs when used to identify infections (− 0.5%, − €886) and to improve patient-ventilator interaction (− 3%, − €264). Both analytics have the potential to save money but the potential benefits of analytics that identify infections strongly depend on infection rate; a higher rate implies greater cost-savings.ConclusionsWe present a framework that stimulates efficiency of development of analytics for big data and artificial intelligence-based solutions by selecting those applications of analytics for which development is feasible and worthwhile. For these applications, results from early economic evaluations can be used to guide investment decisions and identify critical requirements.

Highlights

  • Much has been invested in big data and artificial intelligence-based solutions for healthcare

  • The three use cases focused on chronic lymphocytic leukaemia (CLL), the intensive care unit (ICU) and diabetes

  • The framework was applied to three clinical use cases (e.g. CLL, intensive care and diabetes) (Table 1)

Read more

Summary

Introduction

Much has been invested in big data and artificial intelligence-based solutions for healthcare. Economic evaluations can help to improve decision-making by developers of analytics underlying these solutions aiming to increase the likelihood of successful implementation, but recommendations about their use are lacking. The aim of this study was to develop and apply a framework that positions best practice methods for economic evaluations alongside development of analytics, thereby enabling developers to identify barriers to success and to select analytics worth further investments. With the increasing ability to collect healthcare data, billions of dollars have been invested in (big) data analytics and artificial intelligence (AI) by private (e.g. IBM, Google, hospitals) and public institutions worldwide (e.g. Agency for Healthcare Research and Quality, the PatientCentered Outcomes Research Institute, European Commission) [1,2,3,4,5,6,7,8,9]. Despite many publications on the potential of big data analytics and AI, few analytics have been implemented [6, 17,18,19,20] and resulted in health benefits and/or cost savings [21,22,23]

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.